1例53岁男性小肠间质瘤患者术后给予伊马替尼400 mg口服、1次/d，1个月后患者出现嗜酸粒细胞增多，未积极治疗，继续伊马替尼治疗。4个月后，患者出现双手、双足、腹部水肿疼痛，皮疹逐渐累及全身，胸、背部部分皮肤可见溃烂，全身散在多发斑丘疹伴溃烂、渗液、瘙痒、疼痛。嗜酸粒细胞计数2.7×10n 9/L。结合骨髓穿刺及皮肤活检结果，诊断为嗜酸粒细胞增多、药物性皮疹，考虑为伊马替尼所致。临床药师参与多学科会诊，分析患者出现的不良反应与药物的相关性，建议停药，后续使用应监测伊马替尼血药浓度，调整给药剂量。医师暂停伊马替尼治疗，给予糖皮质激素和抗组胺药物治疗，患者皮疹好转，伊马替尼减量后继续维持治疗。n “,”A 53-year-old male patient with small intestinal stromal tumor received imatinib 400 mg orally once daily after surgery. One month later, the patient developed eosinophilia, but it was not treated. Imatinib was continued. Four months later, edema and pain appeared in the hands, feet, and abdomen, which gradually spread to the whole body; ulcers appeared in part skin of the chest and back, and multiple maculopapular and ulcers were scattered throughout the whole body, accompanied by ulceration, exudation, itching, and pain. Eosinophil count was 2.7×10n 9/L. Combined with the results of bone marrow aspiration and skin biopsy, it was diagnosed as eosinophilia and drug-induced rash, which were considered to be caused by imatinib. Clinical pharmacists participated in multidisciplinary consultation, analyzed the relationship between the adverse reactions and the drugs, and recommended stopping the drug, monitoring the blood concentration of imatinib for subsequent use, and adjusting its dosage. Doctors suspended imatinib treatment, and glucocorticoids and antihistamines were given. Then the patient′s rash was improved, and imatinib was continued at a reduced dose.n